MORPHOSYS AG O.N. | 82.54 / +0.54% |
Date/Time | 03/09 / 09:13 |
Chg. / Chg.(%) | 0.44 / +0.54% |
Bid | 82.46 / 3 |
Ask | 82.56 / 50 |
Open | 82.50 |
Previous Close | 82.10 |
High | 82.84 |
Low | 81.66 |
Volume [EUR] | 765,330.74 |
Volume [Units] | 9,312 |
Price fixings | 114 |
ISIN | DE0006632003 |
Security | MOR |
Exchange | Xetra |
Type | Stock |
Exchange | Last | Volume | |
---|---|---|---|
Xetra | 82.54 | ![]() |
9,312 |
Cboe Europe .. | 82.58 | ![]() |
4,059 |
TradeGate | 82.440 | ![]() |
3,082 |
Turquoise | 81.94 | ![]() |
889 |
London Inter.. | 82.68 | ![]() |
522 |
Stuttgart | 82.060 | ![]() |
74 |
Frankfurt | 82.5000 | ![]() |
30 |
gettex | 82.400 | ![]() |
22 |
Vienna Globa.. | 81.98 | ![]() |
0 |
Hannover | 82.00 | ![]() |
0 |
Berlin | 82.02 | ![]() |
0 |
München | 82.02 | ![]() |
0 |
Hamburg | 82.00 | ![]() |
0 |
Düsseldorf | 82.02 | ![]() |
0 |
Lang & Schwa.. | 82.460 | ![]() |
|
Nasdaq Other.. | 98.7900 | ![]() |
20,563 |
Cboe Europe .. | 81.90 | 128 | |
Cboe Europe .. | 82.95 | 110 | |
EUREX | Options |
News
- I-Mab and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Trial of TJ202/MOR202 in r/r Multiple Myeloma in Mainland China
04/27/2020 / 22:01 - GlobeNewswire - MOR106 clinical development in atopic dermatitis stopped for futility
10/28/2019 / 21:45 - GlobeNewswire - Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients
04/23/2019 / 22:02 - GlobeNewswire - Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients
04/23/2019 / 22:01 - GlobeNewswire - Genmab Announces that the Patent Infringement Lawsuit Relating to DARZALEX® is Over
01/31/2019 / 13:36 - GlobeNewswire